B Lynne Parshall Sells 5,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) Director B Lynne Parshall sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $71.48, for a total value of $357,400.00. Following the transaction, the director owned 10,784 shares in the company, valued at approximately $770,840.32. This trade represents a 31.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Price Performance

CYTK opened at $71.93 on Thursday. The business has a fifty day simple moving average of $79.60 and a 200 day simple moving average of $72.41. The company has a market capitalization of $8.95 billion, a PE ratio of -9.96 and a beta of 0.36. Cytokinetics, Incorporated has a 1 year low of $47.22 and a 1 year high of $88.31.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, topping the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million for the quarter, compared to the consensus estimate of $17.59 million. During the same quarter in the previous year, the business earned ($1.12) EPS. The firm’s quarterly revenue was down 57.1% on a year-over-year basis. Equities analysts anticipate that Cytokinetics, Incorporated will post -6 earnings per share for the current fiscal year.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: New Phase 3 progress in non-obstructive hypertrophic cardiomyopathy (HCM) expands aficamten’s potential market beyond obstructive HCM. Additional study findings also suggest benefits across both forms of the disease, strengthening the outlook for Cytokinetics’ lead cardiovascular program. Cytokinetics Reaches a Phase 3 First in Non-Obstructive HCM Can CYTK’s Aficamten Strengthen Its HCM Growth Prospects?
• Positive Sentiment: Evercore ISI and Goldman Sachs reaffirmed their Buy ratings on CYTK, while HC Wainwright also maintained its Buy recommendation. The repeated endorsements reinforce the favorable sell-side view of Cytokinetics’ pipeline and commercial potential. Evercore ISI Remains a Buy on Cytokinetics Goldman Sachs Reaffirms Its Buy Rating on Cytokinetics
• Neutral Sentiment: Management will participate in a Citi BioPharma investor conference on September 9. The event could provide pipeline or regulatory updates, but the announcement itself contained no new financial or clinical data. Cytokinetics to Participate in September Investor Conferences
• Negative Sentiment: CEO Robert Blum sold 7,500 shares for approximately $526,800, and director B. Lynne Parshall sold 5,000 shares for about $357,400. Both transactions were made under pre-arranged Rule 10b5-1 plans, which reduces their usefulness as signals of current management sentiment, but the sales may weigh modestly on investor confidence.
• Negative Sentiment: Cytokinetics remains unprofitable, with analysts expecting a substantial full-year loss. Its latest quarterly revenue also declined year over year, leaving the stock dependent on clinical and regulatory execution rather than current earnings.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can lifted its stake in Cytokinetics by 1.2% during the fourth quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company’s stock worth $845,000 after purchasing an additional 160 shares during the last quarter. Kennedy Capital Management LLC boosted its holdings in shares of Cytokinetics by 1.2% in the 4th quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company’s stock valued at $838,000 after purchasing an additional 162 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of Cytokinetics by 46.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 171 shares during the last quarter. Vident Advisory LLC raised its holdings in shares of Cytokinetics by 1.4% during the 4th quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company’s stock worth $1,046,000 after buying an additional 234 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its holdings in shares of Cytokinetics by 6.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,723 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 239 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on CYTK. Stifel Nicolaus lifted their price objective on shares of Cytokinetics from $98.00 to $108.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. JPMorgan Chase & Co. increased their target price on shares of Cytokinetics from $97.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Mizuho lifted their price target on shares of Cytokinetics from $100.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, June 24th. Wells Fargo & Company increased their price target on Cytokinetics from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Cytokinetics in a report on Friday, August 7th. Eighteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $103.37.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.